《大行報告》富瑞大幅下調藥明生物(02269.HK)目標價至90元 評級「買入」
富瑞發表報告指,藥明生物(02269.HK)去年銷售按年升48%、經調整後每股盈利按年升51%,而現金餘額達87億元人民幣,其負債比率8%,現金流按年轉正至1億元人民幣。
該行指,管理層指引約120個新計劃及資本支出達60億元人民幣,並預計收入錄按年升30%的增長,包括非新冠相關項目按年升60%,而管理層預料未來三年的收入複合年均增長率將達到30%。
該行表示,預料公司未來三年盈利年均複合增長率介乎26%至27%,並將其目標價由200元大幅下調至90元,維持其評級為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.